Mepolizumab linked to sustained airway remodeling benefits at 3 years

The MESILICO study followed 47 severe asthma patients initiating mepolizumab, with 35 completing 3 years of treatment and 25 undergoing repeat bronchoscopy. The study reported sustained reductions from baseline in sub-basement membrane thickness, airway smooth muscle area and thickness, epithelial damage, and tissue eosinophil numbers, alongside improvements in lung function, biomarkers, and exacerbation rates. The authors state this is the first study suggesting sustained IL-5 blockade may contribute to long-term structural airway improvement, possibly consistent with disease modification in severe eosinophilic asthma.

Most relevant for: Patients with severe eosinophilic asthma being treated with long-term mepolizumab therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.